It looks tempting but the 6.6% decline in Australian stimulated cycles ....gives a H1FY18 outlook of 20% decline in NPAT....I know there are other cost contributing to the NPAT revision but from first glance it seems to indicate a fair degree of fixed cost or discounting...
As for margin....I don't think their EBITA margin drop (from competition) will always out pace their growth in revenue....as an extreme example if their EBITA margin drops from 30% to 22% (~35% reduction) then revenue has to go up by 50% to maintain EBITA.....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
68.5¢ |
Change
0.015(2.24%) |
Mkt cap ! $266.8M | |||
| Open | High | Low | Value | Volume |
| 67.5¢ | 70.0¢ | 66.5¢ | $3.095M | 4.520M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 87358 | 68.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.5¢ | 14948 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MVF (ASX) Chart |